Vanguards of Health Care: Insilico on AI Use in Drug Discovery
“This deal [with Eli Lilly, announced Sunday March 29] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one...
By Annalisa Tulipano · Bloomberg
“This deal [with Eli Lilly, announced Sunday March 29] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,” says Alex Zhavoronkov, founder and co-CEO of Insilico Medicine. Zhavoronkov joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to explain how Insilico is using AI to compress drug-discovery timelines from years to months, pursue novel targets and compe